New cell therapy aims to slow vision loss in retinal disease
NCT ID NCT07594236
First seen Jun 27, 2026 · Last updated Aug 11, 2026 · Updated 4 times
Summary
This early-stage study tests a new treatment called C.001 for people with retinal diseases that cause vision loss, such as geographic atrophy and Stargardt disease. The treatment is given as a single injection into the eye. The main goal is to check if it is safe, and researchers will also look for any changes in vision or eye structure over 12 months.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AGE-RELATED MACULAR DEGENERATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Palo Alto Medical Foundation
NOT_YET_RECRUITINGPalo Alto, California, 94301, United States
Contact Email: •••••@•••••
-
Retina Vision Consultants
RECRUITINGBeverly Hills, California, 90210, United States
Contact Email: •••••@•••••
-
Retinal Consultants Medical Group
NOT_YET_RECRUITINGSacramento, California, 95825, United States
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a VR maze reveal hidden vision loss in macular degeneration?
- New eye imaging could reveal hidden clues to vision loss
- Can a new eye injection save vision in wet AMD?
- Can stem cells restore vision in stargardt disease? a First-in-Human trial aims to find out
- A new eye camera may spot stressed cells before vision loss begins
- A sharper look at the retina: new imaging technology may spot eye disease earlier